Rapid and sustained T cell-based immunotherapy against invasive fungal disease via a combined two step procedure.

ABSTRACT:

Introduction

Aspergillus fumigatus (Asp) infections constitute a major cause of morbidity and mortality in patients following allogeneic hematopoietic stem cell transplantation (HSCT). In the context of insufficient host immunity, antifungal drugs show only limited efficacy. Faster and increased T-cell reconstitution correlated with a favorable outcome and a cell-based therapy approach strongly indicated successful clearance of fungal infections. Nevertheless, complex and cost- or time-intensive protocols hampered their implementation into clinical application.

Methods

To facilitate the clinical-scale manufacturing process of Aspergillus fumigatus-specific T cells (ATCs) and to enable immediate (within 24 hours) and sustained (12 days later) treatment of patien

SUBMITTER: Tischer-Zimmermann S 

PROVIDER: S-EPMC10114046 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature